HLA-B 5701 Genotype, Abacavir Hypersensitivity, Saliva
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Assisting a physician in developing a therapeutic management strategy for HIV-infected patients
Predicting likelihood of hypersensitivity reactions to abacavir in HIV-infected patients, based on the presence of the HLA-B*5701 allele
Aiding in differentiating between true hypersensitivity to abacavir versus other underlying causes (eg, concomitant infection, reaction to other drugs, or inflammatory disease)
This saliva-based test is especially useful for establishing the HLA-B*5701 genotype in patients who received a heterologous blood transfusion, in the preceding 45 days (6 weeks) or allogeneic bone marrow transplants
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
See Abacavir Hypersensitivity Testing and Initial Patient Management Algorithm in Special Instructions
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR)
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
HLAB 5701 Abacavir Genotype, Saliva